PEG Spacer Adjuvants for Lipophilic Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants for vaccines, such as Pam3CysSK4 lipopeptides, face solubility issues due to lipophilicity, leading to aggregation and reduced bioavailability, which hampers their effectiveness and evaluation in immune response modulation.
Innovation Solution
Development of a new class of TLR-2 ligands with improved bioavailability, represented by compounds of Formula (I), which are designed to enhance immune responses while maintaining solubility and stability, including specific conjugates with antigenic peptides for enhanced immune modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipophilic adjuvants such as Pam3CysSK4 lipopeptides are used to enhance immune response, then immune modulation effectiveness is improved, but solubility deteriorates leading to aggregation and reduced bioavailability
Solution Approach 1:
The patent introduces PEG spacers as intermediary molecules between the lipophilic adjuvant and the antigen. These PEG spacers act as solubility-enhancing mediators that prevent aggregation of the lipophilic components while maintaining their immune-modulating functionality. The PEG spacer serves as a bridge that connects the hydrophobic adjuvant to the hydrophilic antigen, resolving the solubility conflict.
Solution Approach 2:
The patent creates composite conjugate structures combining lipophilic adjuvants, PEG spacers, and antigens into a single molecular entity. This composite approach integrates components with different solubility characteristics into a unified structure that achieves both immune effectiveness and adequate solubility through the synergistic combination of elements.
2Reliability
If lipophilic adjuvants are used to stimulate immune response, then adjuvant activity is improved, but bioavailability deteriorates due to aggregation
Solution Approach 1:
The PEG spacer acts as a solubility-enhancing intermediary that prevents aggregation of the lipophilic adjuvant, thereby improving bioavailability without compromising adjuvant activity. The spacer ensures proper distribution and delivery of the active adjuvant component to target cells.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the adjuvant-conjugate system by introducing PEG spacers that change the hydrophilicity, molecular weight, and spatial configuration of the overall molecule. These parameter changes improve solubility and bioavailability while preserving the immunostimulatory properties.
3Reliability
If conjugates of immunogenic peptides with lipophilic adjuvants are developed, then vaccine potency is improved, but solubility and stability deteriorate
Solution Approach 1:
The PEG spacer serves as a stabilizing intermediary in the conjugate structure, preventing unwanted interactions between the lipophilic adjuvant and antigen that could lead to aggregation or degradation. This intermediary maintains the structural integrity and solubility of the vaccine conjugate.
Solution Approach 2:
The patent develops composite vaccine conjugates that integrate lipophilic adjuvants, PEG spacers, and immunogenic peptides into a single stable molecular entity. This composite structure combines the potent immunostimulatory properties of the adjuvant with the antigen specificity of the peptide, while the PEG spacer ensures overall solubility and stability of the conjugate.
Data Source
AI summary
Adjuvant compounds are described, as well as their conjugates comprising peptide antigens or other immunomodulatory moieties. Also described are methods of modulating immune responses in a subject in need thereof, as well as methods of treating cancer, viral or bacterial infections comprising administering the adjuvant compounds or the conjugates to a subject in need thereof.